Immunome Inc. (IMNM): Price and Financial Metrics


Immunome Inc. (IMNM): $5.29

0.16 (+3.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMNM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMNM Stock Price Chart Interactive Chart >

Price chart for IMNM

IMNM Price/Volume Stats

Current price $5.29 52-week high $9.40
Prev. close $5.13 52-week low $2.09
Day low $5.09 Volume 29,411
Day high $5.33 Avg. volume 193,306
50-day MA $3.99 Dividend yield N/A
200-day MA $4.13 Market Cap 64.15M

Immunome Inc. (IMNM) Company Bio


Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.


IMNM Latest News Stream


Event/Time News Detail
Loading, please wait...

IMNM Latest Social Stream


Loading social stream, please wait...

View Full IMNM Social Stream

Latest IMNM News From Around the Web

Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.

Immunome Inc. (IMNM): Major Improvements, Worth A Look

Immunome Inc. (NASDAQ:IMNM) concluded the trading at $4.72 on Friday, January 06 with a rise of 0.21% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.71 and 5Y monthly beta was reading 0.54 with its price kept floating in the range … Immunome Inc. (IMNM): Major Improvements, Worth A Look Read More »

Stocks Register | January 7, 2023

AbbVie and Immunome Partner to Find New Cancer Treatments

Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome''s technology.

The Dog of Wall Street | January 6, 2023

Immunome Stock Jumps On Discovery Pact With AbbVie

AbbVie Inc (NYSE: ABBV ) and Immunome Inc (NASDAQ: IMNM ) announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome''s Discovery Engine. Immunome will receive an upfront payment of $30 million. It … Full story available on Benzinga.com

Benzinga | January 6, 2023

Immunome up 25% on collaboration with AbbVie with for novel cancer drug targets

AbbVie (ABBV) has signed a collaboration agreement with Immunome (IMNM) to discover up to 10 novel antibody-target pairs for cancer treatments.

Seeking Alpha | January 6, 2023

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery

Wallstreet:Online | January 6, 2023

Read More 'IMNM' Stories Here

IMNM Price Returns

1-mo 139.37%
3-mo 30.30%
6-mo 24.47%
1-year -40.96%
3-year N/A
5-year N/A
YTD 139.37%
2022 -82.95%
2021 33.88%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7011 seconds.